**ISPOR Russia St. Petersburg Chapter**

**Annual Report 2016**

**To:**

**Board of Directors**

**International Society for Pharmacoeconomics and**

**Outcomes Research**

**505 Lawrence Square Boulevard South**

**Lawrenceville, ТО 08648 USA**

**PREPARED BY**

Professor Alexey Kolbin, MD, PhD, Doctor of Science

Head of the Department of Clinical Pharmacology and Evidence-Based Medicine, First Pavlov State Medical University of St. Petersburg; Professor of the Department of Pharmacology, Faculty of Medicine St. Petersburg State University

6 – 8 Lva Tolstogo, St. Petersburg, Russia, 197022

Tel: +79217590449

e-mail: [alex.kolbin@mail.ru](mailto:alex.kolbin@mail.ru)

**Background:**

ISPOR Russia St. Petersburg Chapter was accepted in November 2012.

**President of ISPOR Russia St. Petersburg Chapter**

Alexey Kolbin,

MD, PhD, Doctor of Science, Head of the Department of Clinical Pharmacology and Evidence-Based Medicine, First Pavlov State Medical University of St. Petersburg; Professor of the Department of Pharmacology, Faculty of Medicine St. Petersburg State University.

**Vice President**

Edwin Zvartau,

MD, PhD, Doctor of Science, Professor, Head of the Department of Pharmacology, First Pavlov State Medical University of St. Petersburg

**Executive Director**

Dmitry Belousov

DrPH, MD, CEO of Center for Pharmacoeconomics Research

**External Relations Director**

Zakhar Golant,

PhD in Economics, Vice-Rector for Development of Chemical-Pharmaceutical Academy of St. Petersburg

**Secretary**

Alexey Kurilev, MD

Department of Clinical Pharmacology and Evidence-Based Medicine, First Pavlov State Medical University of St. Petersburg;

e-mail: alexey-kurilev@yandex.ru

**Members of the ISPOR Russia St. Petersburg Chapter:**

Alexandra Burbello, MD, PhD, Doctor of Science, Nord-West State Medical University, Professor; Alla Rudakova, PharmD, PhD, Doctor of Science, SPbCPhA, Professor; Andrey Pavlysh, MD, PhD, Doctor of Science, Oncology Institute; Boris Andreev, MD, Doctor of Science, professor, St. Petersburg State University, Head of the department of pharmacology; Georgy Manikhas, MD, PhD, Doctor of Science, City Oncological Clinic, Heard; Yulia Balykina, PhD, St Petersburg State University, associate professor; Maksim Proskurin, MS, St Petersburg State University, Assistant; Julia Gomon, DrPH, MD, St.George the Martyr City Hospital, Clinical pharmacologist; Nikolai Klimko, MD, PhD, Doctor of Science, North-Western State Medical University, Head of the department; Sergey Zyryanov, MD, PhD, Doctor of Science, Russian State Medical University, Professor, Head of the laboratory of clinical pharmacology; Oleg Karpov, MD, PhD, Doctor of Science, Professor, Sanofi, Head of Health Economics and Pricing Policy, Market Access Dept; Natalia Zakharova, MD, PhD, Doctor of Sciences, Professor, North-Western State Medical University.

***For more information of Chapter, please visit at*** <http://www.ispor.org/regional_chapters/Russia-StPetersburg/index.asp> and <http://www.labclinpharm.ru>.

**Activites of the Chapter can be summarized as follows**

**I. The following articles have been published in Russian and International journals on pharmacoeconomic and health technology assessment researches:**

|  |  |  |  |
| --- | --- | --- | --- |
| № | Title | Journal | Author |
| 1. | Brentuximab vedotin in therapy of the recurred or refractory CD30+ systematic anaplastic large cell lymphoma in group of adult patients. | Clinical pharmacology and therapy. 2016;25 (2):91-96. | A. Kolbin, I. Vilum, M. Proskurin, Yu. Balykina |
| 2. | Economical analysis of Lixisenatide in patients with diabetes mellitus type 2. | Good Clinical Practice. 2015; 4:53-64. | A. Kolbin, A. Mosikian, A. Kurilev, Yu. Balykina, M. Proskurin, V.Chgao |
| 3. | Pharmacoeconomic analysis of Telavancin use in in Russian healthcare system for treatment of patients with nosocomial pneumonia. | Pharmacoeconomic: theory and practice. 2016;4(2):88-92. | A. Kolbin, I. Vilum, M. Proskurin, Y. Balykina |
| 4. | Pharmacoeconomic analysis of Telavancin use in in Russian healthcare system for treatment of patients with complicated skin and soft tissues infections. | Pharmacoeconomic: theory and practice. 2016;4(2):75-81. | A. Kolbin, I. Vilum, M. Proskurin, Y. Balykina |
| 5. | Mathematical model of reimbursement decision making in Russia. Results of VIM List for 2016. | Pharmacoeconomics. Modern Pharmacoeconomics and Pharmacoepidemiology. 2016; 1:34-38. | A. Kolbin, A. Prasolov, E. Maksimkina, Y.Balykina, Z. Golant, Y. Polushin, A. Kurylev, I. Vilum |
| 6. | Comparative clinicoepidemiological analysis of diabetes type 1 outcomes among patients with Insulin glargine or degludec as a part basis-bolus treatment. | Pharmacoeconomics: theory and practice. 2016; 4(1):1-5. | A.Kolbin V.Chzhao, A.Kurylev, Y. Balykina, M. Proskurin |
| 7. | Comparative clinical and economic analysis of the outcomes of type 1 diabetes mellitus (T2DM) treated with Insulin glargine or Insulin degludec as a part basis-bolus therapy. | Pharmacoeconomics: theory and practice. 2016;4(1):209. | A.Kolbin, V.Chzhao, A.Kurylev, Y. Balykina, M. Proskurin |
| 8. | Comparative clinical and economic analysis of the outcomes of type 2 diabetes mellitus (T2DM) treated with Insulin glargine or Insulin degludec in combination with oral antidiabetic agents (OAD). | Pharmacoeconomics: theory and practice. 2016;4(1):211. | A.Kolbin, V.Chzhao, A.Mosikian, A. Kurylev,  Y. Balykina, M. Proskurin |
| 9. | National guidelines of using drugs (formulary system). | Edition XVII, M.:Vidoks, 2016.-1045 p. | Authors, edited A.G.Chuchalina |
| 10. | A mathematical model for predicting the development of bacterial resistance based on the relationship between the level of antimicrobial resistance and the volume of antibiotic consumption. | EV0342 ePoster Viewing Resistance surveillance & epidemiology: Gram-negatives. ECCMID, 2016. | A. Kolbin, R. Lawson, A. Kurylev, K. Ryan, M. Arepeva, Y. Balykina, A. Spiridonova, N.Mukhina, S. Sidorenko |
| 11. | Pharmacoeconomic analysis of treatment among patients with severe uncontrolled asthma in Russia. | Practical pulmonology. 2015;4:10-17. | A. Kolbin, M. Frolov, T. Galankin |
| 12. | Analysis of compilation of the restrictive inventories in the Russian Federation as exemplified with “Vital essential and Indispensable Drugs” (VEID): the role of Pharmacoeconomics. | HIV-infection and immunosuppression. 2016;8(2):71-77. | A.Kolbin, A. Prasolov, E. Maksimkina, Y.Balykina, Z. Golant, Y.Polushin, A. Kurylev, I. Vilum |
| 13. | Pharmacoeconomic analysis of omalizumab therapy among children with severe uncontrolled asthma: data from real clinical practice in Russia. | Pediatric Pharmacology. 2016;13(4):345-354. | A.Kolbin, L. Namazova-Baranova, E. Vishneva, et al. |
| 14. | Development of a Search Engine for the MEDLINE Database with Search Results Ranking from the Perspective of Evidence-Based Medicine. | Value in health. Ispor 19th Annual European Congress research abstracts. 2016, Vienna, Austria. PRM69.- A369. | A.Kolbin, M.Kamalov, Y.Balykina, V.Dobrynin, E.Verbitskaya. |
| 15. | Parametric and non-parametric approaches for predicting bacterial resistance. | Value in health. Ispor 19th Annual European Congress research abstracts. 2016, Vienna, Austria. PHP15.-A441. | M. Arepyeva, A. Kolbin, A.Kurylev, Yu. Balykina, A. Spiridonova,N. Mukhina, S. Sidorenko |
| 16. | Development of Predictive Models for the Analysis of the List of Vital Essential and Necessary Drugs Compilation. | Value in health. Ispor 19th Annual European Congress research abstracts. 2016, Vienna, Austria. PHP50.-A448. | A.Kolbin, A.Prasolov, Y. Balykina, E.Maksimkina, Z. Golant, Y.Polushin, A.Kurylev, I.Vilum |
| 17. | Pharmacoeconomic analysis of treatment of adult patients with severe uncontrolled asthma with omalizumab in Russia. | Value in health. Ispor 19th Annual European Congress research abstracts. 2016, Vienna, Austria. PRS38.-A555. | A.Kolbin, M. Frolov, T.Galankin |
| 18. | Pharmacoeconomic analysis of treatment of children with severe uncontrolled asthma with omalizumab in Russia. | Value in health. Ispor 19th Annual European Congress research abstracts. 2016, Vienna, Austria. PRS37.-A555. | A.Kolbin, L. Namazova-Baranova, E. Vishneva, M.Frolov, T. Galankin, A. Alekseeva, E.Dobrynina |
| 19. | Low-density lipoprotein cholesterol lowering efficacy of evolocumab may reduce need for apheresis in heterozygous familial hypercholesterolaemia patients according to Russian guidelines. | Value in health. Ispor 19th Annual European Congress research abstracts. 2016, Vienna, Austria. PCV101.-A654. | T.Gonzalez, A.Kurylev, A.Kolbin, T.Zinina, E.Sidelnikov, G.Villa |
| 20. | Prognostic model of bacterial resistance based on the relationship between antibiotics resistance and consumption. | Clinical Microbiology and Antimicrobial Chemotherapy. 2016;18(3):200-211. | M. Arepeva, A. Kolbin, S. Sidorenko, A. Kurylev, Y. Balykina, N. Mukhina, A. Spiridonova |
| 21. | Cost of additional effectiveness of antineoplastic drugs (according to restrictive lists). | Remedium. 2016;11:42-46. | A. Kolbin, E. Maksimkina, A. Kurylev |
| 22. | Health economic assessment of antirheumatic drugs in patients with reumathoid arthritis progressed after methotrexate. | Pharmacoeconomics. Modern pharmacoeconomics and pharmacoepidemiology. 2016;9(3):20-28. | A.Kolbin, A.Kurylev, M. Proskurin, Y.Balykina |
| 23. | Pharmacoeconomic aspects of Levodopa-Carbidopa Intestinal Gel in Advanced Stages of Parkinson’s Disease. | Medical technology. Assessment and choiсe. 2016;1(23):74-79. | А.Rudakova, A.Skoromets, A.Timofeev |
| 24. | Socioeconomic outcomes of alcoholism in Russia and possible ways to reduce negative consequences. | Narсology. 2016;15(170):49-58. | L.Popovich, E.Potapchik E, Rudakova A. |
| 25. | Effectiveness of expenditure for nalaprevir in hepatitis C therapy (genotype 1) among naive patients and patients with relapse. | Journal of infectology. 2016;3:122-125. | D.Gusev, A.Rudakova, A.Uskov, L.Konovalova, Y.Lobzin |
| 26. | Analysis of vaccination effectiveness among adult patients against flu. | Medicine of extreme situations. 2016; 2(56):25-29. | A.Rudakova, S.Harith, A.Uskov, Y. Lobzin |
| 27. | Expensiveness of expenditure for second protease inhibitors hepatitis C therapy (genotype 1) among naive patients and patients with relapse. | Journal of infectology. 2016;1:79-82. | A.Rudakova, D.Gusev, A.Uskov, L.Konovalova, Y. Lobzin |
| 28. | Fixed combination of Calcipotriol and Betamethasone In psoriasis therapy: analysis of data base. | Clinical Dermatology and Venerology. 2016;15(2): 85-90. | A.Rudakova, A.Lvov |
| 29. | Dipeptidylpeptidase-4 inhibitors in diabetes type 2 therapy. | Coll. research papers XI International Scientific Congress "Rational pharmacotherapy" .- SPb.: Publishing house SPbGEU, 2016:131-132. | A.Rudakova |
| 30. | Budget impact analysis of antiplatelet therapy with Ticagrelorand Clopidogrel in patients with acute coronal syndrome after coronary artery bypass surgery. | Therapeutic Archives. 2016;88:39-49. | S.Zyryanov, D. Belousov, E.Afanasyeva, E. Dumchenko |
| 31. | Pharmacoeconomic efficacy of Insulin in combination with Vildagliptin in patients with type 2 diabetes. | Clinical Pharmacology and Therapy. 2016; 25(4):92-96. | S. Zyryanov, I. Dyakov |
| 32. | Pharmacoeconomic assessment of urinary tract infections in infants born to mothers with pathological pregnancy. | Kuban Research Medical Gazette. 2016;2 (157):156-160. | O.Shulakova, K.Gurevich, S.Zyryanov |
| 33. | Pharmacoeconomic analysis of drugs: What is important for physician? | Effective pharmacotherapy. 2016;11:40-45. | S.Zyryanov, Z.Galeeva |
| 34. | The economic prognosis of the new analogue of insulin glargine usage in diabetes mellitus type 2. | Good Clinical Practice. 2016;2:5-13. | D.Belousov, E.Afanasyeva |
| 35. | Pharmacoeconomic analysis of Xeomine® for treatment patients with focal dystonia. | Good Clinical Practice. 2016;2:14-23. | S.Zyryanov, D.Belousov, A. Cheberda |
| 36. | Pharmacoeconomic analysis of naftidrofuryl for treatment of ischemic stroke. | Good Clinical Practice. 2016;2:29-37. | A.Cheberda, D.Belousov, A. Bogolepova |
| 37. | Clinical-economic analysis of valproate microsphere form in focal epilepsy in adults (real world evidences). | Good Clinical Practice. 2016;1:4-13. | D.Belousov, L.Bistritskaya, E.Afanasyeva |
| 38. | Comparative pharmacoeconomic analysis of Paclical® and Taxol® in the Russian Federation. | Good Clinical Practice. 2016;1:14-24. | A.Cheberda, D.Belousov |
| 39. | Comparative pharmacoepidemiological study of antihyperglycemic drugs utilization by patients with type 2 diabetes mellitus in Moscow. | Diabetes Mellitus. 2016;19(3):260-272 | M.Kalashnikova, D.Belousov, M.Kantemirova, M.Аntsiferov |
| 40. | Comparative pharmacoeconomic analysis of oxycodone/naloxone combination analgesic and fentanyl transdermal delivery system. | Good clinical practice. 2016. – 3. – in print. | A.Cheberda, D.Belousov |
| 41. | Pharmacoeconomic analysis of Actemra® as second-line treatment for rheumatoid arthritis resistant to first-line biological therapy, and as first-line treatment. | Good clinical practice. 2016. – 3. – in print. | S.Zyryanov, A.Cheberda, D. Belousov |
| 42. | Pharmacoeconomic analysis of Perchloson® for treatment of multidrug-resistant tuberculosis. | Good clinical practice. 2016. – 3. – in print. | D.Belousov, A.Cheberda |
| 43. | Review the results of pharmacoeconomic trials of antiplatelet drugs in the treatment of patients with acute coronary syndrome. | Good clinical practice. 2016. – 3. – in print. | S.Zyryanov, E.Dumchenko |

**II. Oral and Poster Presentations at the ISPOR International and European Meeting:**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| № пп. | Conference Title | Paper Title  / ORAL PRESENTATION | Date | Venue |
| 1 | ISPOR 19th Annual European Congress | Development of a Search Engine for the MEDLINE Database with Search Results Ranking from the Perspective of Evidence-Based Medicine | 2016 | Vienna, Austria. |
| 2 | ISPOR 19th Annual European Congress | Parametric and non-parametric approaches for predicting bacterial resistance | 2016 | Vienna, Austria. |
| 3 | ISPOR 19th Annual European Congress | Development of Predictive Models for the Analysis of the List of Vital Essential and Necessary Drugs Compilation | 2016 | Vienna, Austria. |
| 4 | ISPOR 19th Annual European Congress | Pharmacoeconomic analysis of treatment of adult patients with severe uncontrolled asthma with omalizumab in Russia | 2016 | Vienna, Austria. |
| 5 | ISPOR 19th Annual European Congress | Pharmacoeconomic analysis of treatment of children with severe uncontrolled asthma with omalizumab in Russia | 2016 | Vienna, Austria. |
| 6 | ISPOR 19th Annual European Congress | Low-density lipoprotein cholesterol lowering efficacy of evolocumab may reduce need for apheresis in heterozygous familial hypercholesterolaemia patients according to Russian guidelines | 2016 | Vienna, Austria. |
| 7 | ISPOR 19th Annual European Congress | The cost of additional effectiveness of anticancer drugs according to the restrictive lists of Russia | 2016 | Vienna, Austria. |

**III. Oral Presentations at the Russian Meeting on health economics and health technology assessment researches**:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| № пп. | Conference Title | Organizers | Paper Title | Venue |
| 1. | 4th International science and practice symposium «HIV-medicine and pharmacoeconomic. Economic questions in HIV epidemiology, prophylaxis, diagnostics and clinic». | Saint-Petersburg Health Care Committee. | Analysis of restrictive lists compilation in Russian Federation on the example of restricted list. Role of Pharmacoeconomics. | Saint-Petersburg |
| 2. | Therapy access: from recommendations to real practice. New opportunities of curing patients with severe uncontrolled asthma. | Ministry of Health. | Pharmacoeconomic aspects of the use of omalizumab in patients with severe asthma. | Moscow |
| 3. | XXIII National Russian congress “Human and medicine” | Ministry of Health. | Systemic antimycotics: who, when, what, how much? | Moscow |
| 4. | Russian conferention «Actual questions of clinical pharmacology and drugs support». | Ministry of Health. | Simulation incorporating drugs into dosage lists. | Pyatigorsk |
| 5. | IV Russian conferention “Actual questions of preclinical and clinical trials of drugs and medical products”. | Ministry of Health. | Choosing generic drugs based on HTA. The role of the observational study. | Saint-Petersburg |
| 6. | Russian-Chinese scientific and practical conference on medical microbiology and clinical mycology. XIX Kashkinskie chtenia. | Russian Ministry of Health. | Pharmacoepidemiology of antibiotics in perinatology. | Saint-Petersburg |
| 7. | Scientific and practical conference on Diabetes – social and economic burden. | Saint-Petersburg Ministry of Health. | Pharmacoeconomic modeling based on real clinical practice (diabetes). | Saint-Petersburg |
| 8. | Discussion committee «Pharmacoeconomic analysis of breast cancer». | Russian Ministry of Health. | Who or what could influence on route of drug administration? (physician, patient or government). | Sochi |
| 9. | Saint-Petersburg septic forum. | Saint-Petersburg Ministry of Health. | Pharmacoepidemiology of antibiotics in neonatology. | Saint-Petersburg |
| 10. | ХI International scientific congress “Rational pharmacotherapy”. | Russian Ministry of Health. | Pharmacoepidemiology of antibiotics in Saint-Petersburg – «from children to adult». | Saint-Petersburg |
| 11. | ХI International scientific congress “Rational pharmacotherapy”. | Russian Ministry of Health. | Experience of algorithm development of clinical trials ranking according to the level of their conclusiveness. | Saint-Petersburg |
| 12. | Scientific and practical international conference «HIV-infection and immunosuppression. HIV-associated severe and comorbid conditions. Epidemiology and modern strategies». VIII Vinogradovskie Chtenia. | Russian Ministry of Health, Russian Scientific Academy. | Selection of generic drugs based on health care technology assessment. | Saint-Petersburg |
| 13. | Russian conference on «Actual questions of clinical oncology ». | Profile Committee of the Russian Ministry of Health specialty "oncology" State Organization "Russian Scientific Centre of Oncology. N.N. Blokhin" of the Russian Ministry of Health "Russian Association of Oncologists". | Cost of additional effectiveness of anticancer agents. | Moscow |
| 14. | II Russian conference with international participation. “Perinatal medicine: from pregravid preparation to healthy mothercare and childhood”. | Saint-Petersburg Healthcare Committee. | Pharmacoeconomic aspects of vicarious surfactant therapy of premature infants with respiratory distress syndrome. | Saint-Petersburg |
| 15. | ХХVIII Summary scientific practical conference «Actual questions of infectious diseases among children-2016». | Saint-Petersburg Healthcare Committee. | Pharmacoeconomic aspects of prophylaxis and therapy of infectious diseases. | Saint-Petersburg |
| 16. | II nd International oncology forum «White nights». | Saint-Petersburg Healthcare Committee. | Pharmacoeconomic aspects of metastatic melanoma therapy. | Saint-Petersburg |
| 17. | XI international scientific congress «Rational pharmacotherapy». | Saint-Petersburg Healthcare Committee. | Pharmacoeconomic aspects of the use of inhibitors of dipeptidyl peptidase 4 types for type 2 diabetes mellitus treatment. | Saint-Petersburg |
| 18. | Scientific and practical international conference «HIV-infection and immunosuppression. HIV-associated severe and comorbid conditions. Epidemiology and modern strategies». | Healthcare Committee. | Pharmacoeconomics of HIV – infection therapy. | Saint-Petersburg |
| 19. | Russian conference with international participation «Innovation technologies in physiatry» in memory of academic RSA M.I. Perelman. | Russian Science Academy. | Pharmaeconomic aspects of tuberculosis pathogen drug susceptibility by phenotypic methods. | Moscow |
| 20. | As a section of II-nd International oncology forum “White Nights -2016”. | Russian Ministry of Health, The Association of Oncologists of Russia, Petrov Federal Research Institute Of Oncology. | ABC/VEN-analysis in oncology: results and prospects. | Saint-Petersburg |
| 21. | 11th international scientific congress «Rational Pharmacotherapy». | Healthcare Committee of Saint Petersburg, Regional NGO “Professional medical Association of clinical pharmacologists of Saint Petersburg”. | Pharmacoeconomic aspects of using Perampanel for treatment of drug-resistant epilepsy. | Saint Petersburg |

**IV. Doctoral thesis** on "The pharmacoeconomic evaluation of the effectiveness of chemotherapy in cancer care system". Andrey Pavlysh, MD, PhD, Doctor of Science, Oncology Institute; 05/04/2016, Saint-Petersburg, Russia.

**V. Journals where we are editors and can provide ideology and methodology of pharmacoeconomics and health technology assessment**

Good Clinical Practice. [www.clinvest.ru](http://www.clinvest.ru)

#### VI. Chapter accomplishments for 2016 with regard to Policy-related activities

1. Modelling the inclusion of drugs in the Russian government reimbursement lists. This research has been presented to the Federal Ministry of Health.

2. Conducting the pharmacoepidemiology research for the State Insurance Fund on using antibiotics in state hospitals in Saint-Petersburg, Russia.

**VII. Our websites**

1. <http://www.labclinpharm.ru>
2. <http://www.healtheconomics.ru>

**VIII. Our plans**

In the spring of 2017 three events are planed:

1.HTA symposium is planed within the framework of the “XXI ANNUAL SCIENTIFIC SESSION OF THE INSTITUTE OF PHARMACOLOGY” conference. The symposium is called "Actual Problems of Health Technology Assessment". The symposium will consist of 6 oral presentations. The organizer is Saint Petersburg Medical University. The conference is to be on January 27, 2017. Saint-Petersburg, Russia.

1. 2.HTA symposium is planed within the framework of the “Rational pharmacotherapy in Physician Practices” conference. The symposium is called "Choosing Generic on the Basis of the Principles of the НTA". The symposium will consist of 3 oral presentations. The organizer is Health Committee of Saint Petersburg. The conference is to be on February 18, 2017. Saint-Petersburg, Russia.
2. 3.HTA symposium is planed within the framework of the "Safety of Drugs" conference. The symposium is called "Current Drug Safety Issues in Health Technology Assessment". The symposium will consist of 3 oral presentations. The organizer is Health Committee of Saint Petersburg. The conference is to be on 24 - 25 March, 2017. Saint-Petersburg, Russia.